<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00792077</url>
  </required_header>
  <id_info>
    <org_study_id>2007-0945</org_study_id>
    <secondary_id>NCI-2012-01661</secondary_id>
    <nct_id>NCT00792077</nct_id>
  </id_info>
  <brief_title>A Pilot Study to Investigate the Effect of Cytotoxic Therapy and/or Radiotherapy on Cancer Related Sleep Disturbances in CLL and Breast Cancer Patients Experiencing Fatigue</brief_title>
  <official_title>A Pilot Open Label Study to Investigate the Effect of Cytotoxic Therapy and/or Radiotherapy Including Lenalidomide on Cancer Related Sleep Disturbances in Chronic Lymphocytic Leukemia (CLL) and Breast Cancer Patients Experiencing Clinically Significant Fatigue</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if treatments to kill cancer cells&#xD;
      including lenalidomide and/or radiation therapy can help to control symptoms such as sleep&#xD;
      problems and fatigue in patients with chronic lymphocytic leukemia (CLL) and/or breast&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, researchers are trying to learn if treatments to kill cancer cells such as&#xD;
      lenalidomide and/or radiation therapy can also help to control sleep problems and fatigue in&#xD;
      patients with CLL and/or breast cancer.&#xD;
&#xD;
      Study Procedures:&#xD;
&#xD;
      If you are found to be eligible to take part in this study, before you begin taking&#xD;
      chemotherapy on Day 1, the following tests and procedures will be performed:&#xD;
&#xD;
        -  Blood (about 2 tablespoons) will be drawn to learn about the relationship between&#xD;
           changes in specific protein levels in the blood, your level of fatigue, and sleep&#xD;
           problems.&#xD;
&#xD;
        -  Your complete medical history will be recorded.&#xD;
&#xD;
        -  You will have a physical exam.&#xD;
&#xD;
        -  You will also complete 4 questionnaires that will ask you questions about your symptoms&#xD;
           and your sleep patterns. They will take 20-30 minutes to complete in total.&#xD;
&#xD;
      From Day 1 through the end of 1st cycle (+/- 3 days), you will wear a watch that records your&#xD;
      body movements. This is called an actigraph.&#xD;
&#xD;
      On Day 15 (+/- 3 days), you will be called by a member of the research staff. During these&#xD;
      calls, you will complete the 4 questionnaires that ask about symptoms you are having and&#xD;
      about your sleep patterns.&#xD;
&#xD;
      On Day 29 (+/- 3 days) and end of 1st cycle (+/- 3 days), you will have a clinic visit. At&#xD;
      this visit, you will complete the 4 questionnaires that ask about symptoms you are having and&#xD;
      your sleep patterns. Blood (about 2 tablespoons) will also be drawn to learn about the&#xD;
      relationship between changes in protein levels in the blood, your level of fatigue, and sleep&#xD;
      problems.&#xD;
&#xD;
      Sleep Tests:&#xD;
&#xD;
      You will have a sleep test before starting chemotherapy on Day 1 and again on end of 1st&#xD;
      cycle (+/- 3 days). The sleep test is done overnight in a sleep lab.&#xD;
&#xD;
      A sleep study, called a polysomnogram, is a test that records a person's physical state&#xD;
      during various stages of sleep and wakefulness. The study provides information about a&#xD;
      person's sleep stages, body position, blood oxygen levels, breathing events, muscle tone,&#xD;
      heart rate, snoring, and general sleep behavior.&#xD;
&#xD;
      When you arrive at the Sleep Center Laboratory you will be shown to your private room. You&#xD;
      will complete a questionnaire that will ask questions about how much you slept the night&#xD;
      before, how active you have been, and about any caffeine or alcohol you may have had. The&#xD;
      questionnaire will take about 5 minutes to complete.&#xD;
&#xD;
      The member of the sleep lab staff will connect sensors that will record your brain waves,&#xD;
      muscle tone, eye movements, air flow, and limb movements while you sleep. The sensors are&#xD;
      applied to specific areas of your body with paste and gauze or tape. The monitoring equipment&#xD;
      is painless and should not interfere with your sleep.&#xD;
&#xD;
      It is not a problem to have a drink of water or to use the restroom during the sleep study.&#xD;
      The member of the sleep lab staff will monitor the sleep study from another room throughout&#xD;
      the night and will wake you in the morning to remove the sensors.&#xD;
&#xD;
      In the morning, you will complete a questionnaire about how you slept and how you are&#xD;
      feeling. It will take about 5 minutes to complete.&#xD;
&#xD;
      Length of Study:&#xD;
&#xD;
      You will be on study up to end of 1st cycle (+/- 3 days).&#xD;
&#xD;
      This is an investigational study. Sleep studies are a standard test for patients with sleep&#xD;
      problems.&#xD;
&#xD;
      The blood tests performed for this study and the sleep test will be performed at no cost to&#xD;
      you.&#xD;
&#xD;
      Up to 12 patients will take part in this study. All will be enrolled at M. D. Anderson.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2008</start_date>
  <completion_date type="Actual">August 3, 2020</completion_date>
  <primary_completion_date type="Actual">August 3, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Sleep Time as Measured by Polysomnography (PSG)</measure>
    <time_frame>before and after 1st cycle of Lenalidomide treatment, up to 8 weeks</time_frame>
    <description>Polysomnography (PSG) was done to measure the total sleep time in minutes. It was measured as a change in total sleep time between the before and after 1st cycle of treatment with Lenalidomide.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Functional Assessment of Chronic Illness Therapy-Fatigue Subscale Score</measure>
    <time_frame>before and after 1st cycle of Lenalidomide treatment, up to 8 weeks</time_frame>
    <description>The FACIT-F subscale is a validated measure of fatigue. In the FACIT-F, the patient rates the intensity of their fatigue and its related symptoms on a scale of 0 to 4. The total score can range between 0 and 52, with higher scores denoting less fatigue. The score 0= worst fatigue possible, 52 indicates no fatigue. The scores reported is the median (IQR) change at 8 weeks compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epwort Sleep Scale</measure>
    <time_frame>before and after 1st cycle of Lenalidomide treatment, up to 8 weeks</time_frame>
    <description>The Epworth sleep scale is an 8-item questionnaire designed to asses general level of daytime sleepiness, and scores on this instrument range form 0-24, with higher scores indicating greater sleepiness. It was measured as a change in total score between the before and after 1st cycle of treatment with Lenalidomide.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECOG Performance Status</measure>
    <time_frame>before and after first cycle of Lenalidomide treatment, up to 8 weeks</time_frame>
    <description>This criteria is used to assess how a patient's disease is progressing and to assess how the disease affects the daily living abilities of the patient. The scores on this instrument range from 0-5 (0=fully active and 5=dead), with higher scores indicating poorer performance. It was measured as a change in performance status between before and after 1st cycle of treatment with Lenalidomide.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Leukemia</condition>
  <condition>CLL</condition>
  <arm_group>
    <arm_group_label>Sleep time</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Assessment of patients with chronic lymphocytic leukemia (CLL) experience severe cancer related fatigue (CRF):&#xD;
Lenalidomide + Actigraph + Questionnaire + Sleep Test</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>5 mg daily for 56 days.</description>
    <arm_group_label>Sleep time</arm_group_label>
    <other_name>CC-5013</other_name>
    <other_name>Revlimid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Describe fatigue as being present every day for most of day for a minimum of 2 weeks&#xD;
             and rate fatigue greater than or equal to 4 on a 0-10 scale, in which 0= no fatigue&#xD;
             and 10=worst possible fatigue as assessed by MD Anderson symptom Inventory(MDASI).&#xD;
&#xD;
          2. Have diagnoses of CLL and started on a new cytotoxic therapy or breast cancer&#xD;
             receiving new cytotoxic or radiation therapy&#xD;
&#xD;
          3. Patients will be eligible to participate in this study if they rate sleep disturbance&#xD;
             greater than or equal to 4 on a 0-10 scale, in which 0= disturbed sleep is not present&#xD;
             and 10 = disturbed sleep as bad as you can imagine as assessed by MDASI.&#xD;
&#xD;
          4. Have a MDAS of 13 or less.&#xD;
&#xD;
          5. Able to understand the description of the study and give written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who are unable to complete the assessment measures or refuse to participate&#xD;
&#xD;
          2. Patients with known history of brain metastasis.&#xD;
&#xD;
          3. Patients with known history of sleep apnea.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sriram Yennurajalingam, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>The University of Texas M.D.Anderson Cancer Center</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 13, 2008</study_first_submitted>
  <study_first_submitted_qc>November 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2008</study_first_posted>
  <results_first_submitted>June 3, 2021</results_first_submitted>
  <results_first_submitted_qc>June 30, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 1, 2021</results_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leukemia</keyword>
  <keyword>Lenalidomide</keyword>
  <keyword>Actigraph</keyword>
  <keyword>Sleep Test Study</keyword>
  <keyword>Chronic Lymphocytic Leukemia</keyword>
  <keyword>CC-5013</keyword>
  <keyword>Revlimid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Dyssomnias</mesh_term>
    <mesh_term>Parasomnias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 22, 2008</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT00792077/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients with Chronic lymphocytic leukemia were recruited from the Leukemia Clinic at the University of Texas MD Anderson Cancer Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Lenalidomide</title>
          <description>Participants received lenalidomide 5mg orally daily for 57 +/- 3 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Day 15+/- 3 Days</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Day 29+/-3 Days</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Day 43+/-3 Days</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Day 57+/-3 Days</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lenalidomide</title>
          <description>Participants received lenalidomide 5mg orally daily for 57 +/- 3 days</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Marital Status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Divorced</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Married</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Separated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Employment Status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Full Time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medical Leave</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unemployed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Sleep Time as Measured by Polysomnography (PSG)</title>
        <description>Polysomnography (PSG) was done to measure the total sleep time in minutes. It was measured as a change in total sleep time between the before and after 1st cycle of treatment with Lenalidomide.</description>
        <time_frame>before and after 1st cycle of Lenalidomide treatment, up to 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide</title>
            <description>Participants received lenalidomide 5mg orally daily for 57 +/- 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Total Sleep Time as Measured by Polysomnography (PSG)</title>
          <description>Polysomnography (PSG) was done to measure the total sleep time in minutes. It was measured as a change in total sleep time between the before and after 1st cycle of treatment with Lenalidomide.</description>
          <units>Minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.5" lower_limit="-46.0" upper_limit="-15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Functional Assessment of Chronic Illness Therapy-Fatigue Subscale Score</title>
        <description>The FACIT-F subscale is a validated measure of fatigue. In the FACIT-F, the patient rates the intensity of their fatigue and its related symptoms on a scale of 0 to 4. The total score can range between 0 and 52, with higher scores denoting less fatigue. The score 0= worst fatigue possible, 52 indicates no fatigue. The scores reported is the median (IQR) change at 8 weeks compared to baseline.</description>
        <time_frame>before and after 1st cycle of Lenalidomide treatment, up to 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide</title>
            <description>Participants received lenalidomide 5mg orally daily for 57 +/- 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>The Functional Assessment of Chronic Illness Therapy-Fatigue Subscale Score</title>
          <description>The FACIT-F subscale is a validated measure of fatigue. In the FACIT-F, the patient rates the intensity of their fatigue and its related symptoms on a scale of 0 to 4. The total score can range between 0 and 52, with higher scores denoting less fatigue. The score 0= worst fatigue possible, 52 indicates no fatigue. The scores reported is the median (IQR) change at 8 weeks compared to baseline.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="-11" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Epwort Sleep Scale</title>
        <description>The Epworth sleep scale is an 8-item questionnaire designed to asses general level of daytime sleepiness, and scores on this instrument range form 0-24, with higher scores indicating greater sleepiness. It was measured as a change in total score between the before and after 1st cycle of treatment with Lenalidomide.</description>
        <time_frame>before and after 1st cycle of Lenalidomide treatment, up to 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide</title>
            <description>Participants received lenalidomide 5mg orally daily for 57 +/- 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Epwort Sleep Scale</title>
          <description>The Epworth sleep scale is an 8-item questionnaire designed to asses general level of daytime sleepiness, and scores on this instrument range form 0-24, with higher scores indicating greater sleepiness. It was measured as a change in total score between the before and after 1st cycle of treatment with Lenalidomide.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" lower_limit="-3" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ECOG Performance Status</title>
        <description>This criteria is used to assess how a patient's disease is progressing and to assess how the disease affects the daily living abilities of the patient. The scores on this instrument range from 0-5 (0=fully active and 5=dead), with higher scores indicating poorer performance. It was measured as a change in performance status between before and after 1st cycle of treatment with Lenalidomide.</description>
        <time_frame>before and after first cycle of Lenalidomide treatment, up to 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide</title>
            <description>Participants received lenalidomide 5mg orally daily for 57 +/- 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>ECOG Performance Status</title>
          <description>This criteria is used to assess how a patient's disease is progressing and to assess how the disease affects the daily living abilities of the patient. The scores on this instrument range from 0-5 (0=fully active and 5=dead), with higher scores indicating poorer performance. It was measured as a change in performance status between before and after 1st cycle of treatment with Lenalidomide.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>before and after 1st cycle of Lenalidomide treatment, up to 8 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lenalidomide</title>
          <description>Participants received lenalidomide 5mg orally daily for 57 +/- 3 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sriram Yennu, MD- Professor, Palliative Care Med</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <phone>(713) 792-3938</phone>
      <email>syennu@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

